<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="684">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823862</url>
  </required_header>
  <id_info>
    <org_study_id>DV3-HCV-01</org_study_id>
    <secondary_id>2008-001708-22</secondary_id>
    <nct_id>NCT00823862</nct_id>
  </id_info>
  <brief_title>Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection</brief_title>
  <official_title>A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study of SD-101 to Assess the Safety, Pharmacodynamics, and Preliminary Evidence of Anti-Viral Effect in Subjects Diagnosed With Chronic Hepatitis C, Genotype 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synteract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Poland: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101
      alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse event timing, duration, and severity.</measure>
    <time_frame>Between doses and up to 3 months after last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis of blood sample</measure>
    <time_frame>pre and 24 hour post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load in blood sample</measure>
    <time_frame>each visit</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Active (SD-101)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD-101 in cohorts of escalating doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SD-101</intervention_name>
    <description>Intramuscular (IM)</description>
    <arm_group_label>Active (SD-101)</arm_group_label>
    <other_name>CpG Class C Immunostimulatory Sequence (ISS)</other_name>
    <other_name>TLR9 Agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
    <description>oral, 2 times per day, for 2 months</description>
    <arm_group_label>Active (SD-101)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed, written, informed consent

          -  Male or female subjects, 18 to 55 years of age.

          -  Subject must have chronic infection HCV, genotype 1.

          -  Serum HCV-RNA concentrations 100,000 IU/mL to 10,000,000 IU/mL

          -  No prior treatment for HCV.

          -  Must be negative for hepatitis B (HBV) and human immunodeficiency virus (HIV).

          -  Must be willing to use dual method of contraception (i.e., barrier and spermicide;
             birth control pills and barrier) during the study.

          -  No known hypersensitivity to study medication or to drugs chemically related to the
             study.

        Exclusion Criteria:

          -  Prior treatment with IFN-based therapies and/or anti-viral therapies.

          -  Women with ongoing pregnancy or breast feeding and male partners of women who are
             pregnant.

          -  Reduced kidney function.

          -  Presence of concomitant liver diseases

          -  Signs or symptoms of hepatocellular carcinoma.

          -  Thyroid disease currently poorly controlled on prescribed medications.

          -  History of hemoglobinopathy.

          -  Evidence of severe retinopathy.

          -  Other serious medical conditions, including human immunodeficiency virus, cancer
             (excluding non-melanoma skin cancer), or evidence of drug or alcohol abuse.

          -  Subjects with documented or presumed coronary artery disease, pulmonary disease, or
             cerebrovascular disease

          -  Clinically significant acute or chronic illnesses.

          -  History of severe psychiatric disease, especially depression, characterized by a
             suicide attempt, hospitalization for psychiatric disease, or a period of disability
             as a result of psychiatric disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janusz Cianciara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Warszawski Uniwersytet Medyczny</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinika Chorób Zakaźnych i Hepatologii Collegium Medicum Uniwersytet Mikołaja Kopernika</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85 - 030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Chorób Zakaźnych Uniwersytet Medyczny w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-089</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zakaźny - Klinika Hepatologii i Nabytych Niedoborów Immunologicznych</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Zakaźny</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny S.A. Szpital Specjalistyczny z Przychodnią &quot;EuroMediCare&quot;</name>
      <address>
        <city>Wrocław</city>
        <zip>144-148</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 19, 2015</lastchanged_date>
  <firstreceived_date>January 14, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>Immunostimulatory sequence (ISS)</keyword>
  <keyword>TLR9 (toll-like receptor 9)</keyword>
  <keyword>interferon (IFN)</keyword>
  <keyword>ribavirin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
